Table 3. Diagnostic performances of follow-up US-FNA, BRAFV600E mutation analysis, and follow-up US-FNA combined to BRAFV600E mutation.
| All nodules (n = 49) | Follow-up US-FNA | BRAFV600E | Follow-up US-FNA+BRAFV600E | P* | Nodules with suspicious US feature (n = 32) | Follow-up US-FNA | BRAFV600E | Follow-up US-FNA+BRAFV600E | P* |
| Sensitivity | 83.3 (10/12) | 58.3 (7/12) | 91.7 (11/12) | 0.021 | Sensitivity | 83.3 (10/12) | 58.3 (7/12) | 91.7 (11/12) | 0.021 |
| Specificity | 100.0 (37/37) | 100.0 (37/37) | 100.0 (37/37) | - | Specificity | 100.0 (20/20) | 100.0 (20/20) | 100.0 (20/20) | - |
| PPV | 100.0 (10/10) | 100.0 (7/7) | 100.0 (11/11) | - | PPV | 100.0 (10/10) | 100.0 (7/7) | 100.0 (11/11) | - |
| NPV | 94.9 (37/39) | 88.1 (37/42) | 97.4 (37/38) | 0.167 | NPV | 90.0 (20/22) | 80.0 (20/25) | 95.2 (20/21) | 0.289 |
| Accuracy | 95.9 (47/49) | 89.8 (44/49) | 98.0 (48/49) | 0.23 | Accuracy | 93.8 (30/32) | 84.4 (27/32) | 96.9 (31/32) | 0.241 |
Note: Raw data are in parentheses
PPV: positive predictive value, NPV: negative predictive value, *: P values when comparing US-FNA and US-FNA+BRAFV60